Skip to Content

Atovaquone Pregnancy and Breastfeeding Warnings

Atovaquone is also known as: Mepron

Medically reviewed on Mar 8, 2018

Atovaquone Pregnancy Warnings

Atovaquone has been assigned to pregnancy category C. Animal studies have revealed evidence of increased resorption and fetal harm; it is unclear if these effects were due to direct embryotoxicity and fetotoxicity or secondary to maternal toxicity. There are no controlled data in human pregnancies. Atovaquone should only be given during pregnancy when benefit outweighs risk.

See references

Atovaquone Breastfeeding Warnings

There are no data on the excretion of atovaquone into human milk. In a rat study, atovaquone milk concentration was 30% of maternal plasma concentration. The manufacturer recommends that caution be used when administering atovaquone to nursing women. The U.S. Public Health Service Centers for Disease Control and Prevention advise HIV-infected women not to breast-feed to avoid postnatal transmission of HIV to a child who may not yet be infected.

See references

References for pregnancy information

  1. "Product Information. Mepron (atovaquone)." Glaxo Wellcome, Research Triangle Park, NC.

References for breastfeeding information

  1. "Product Information. Mepron (atovaquone)." Glaxo Wellcome, Research Triangle Park, NC.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide